Rankia España Rankia Argentina Rankia Brasil Rankia Chile Rankia Colombia Rankia Czechia Rankia Deutschland Rankia France Rankia Indonesia Rankia Italia Rankia Magyarország Rankia México Rankia Netherlands Rankia Perú Rankia Polska Rankia Portugal Rankia Romania Rankia Türkiye Rankia United Kingdom Rankia USA
Acceder

Threshold Pharmaceuticals, Inc (THLD): Opiniones

12,3K respuestas
Threshold Pharmaceuticals, Inc (THLD): Opiniones
2 suscriptores
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Página
1.437 / 1.539
#11492

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Esto es del dia 14 pasado, lo he visto ahora.
3. Threshold Pharmaceuticals (Nasdaq: THLD)​

View gallery
.
I have been following this biotech firm for several years, acknowledging all the while that investors would need to show patience during the long and arduous phases of clinical trial testing.

Well, the wait is almost over.

Threshold's TH-302, which focuses on oxygen-deprived tumors that are hard to treat with traditional chemotherapy drugs. Though the company is testing a wide range of tumors in Phase I and II clinical trials, it is also conducting Phase III trials for soft tissue sarcoma and pancreatic cancer.

The primary data collection phase for the soft tissue sarcoma trial nearing completion (ClinicalTrials.gov says it was scheduled to be completed in June). Although Threshold won't provide a complete set of analysis to the FDA until next winter, it is expected to release a preliminary look at the data in coming months.

Positive results could send this stock far higher, in part because it would serve as an endorsement for all of the TH-302 earlier-stage trials.
[More from StreetAuthority.com: 6 Stocks With Major Insider Buying]

Risks to Consider: Even armed with solid clinical trial data, some drugs just don't pass muster with the FDA, so no drug is a sure thing, until it is approved.

Action to Take --> Biotech and medtech catalysts often stare investors right in the face, yet still get ignored. I greatly prefer focusing on companies with drugs or devices in Phase II or Phase III trials, simply because earlier-stage trials often end up yielding poor results. These three stocks are poised to deliver solid catalysts in 2014, making this a good time to listen to their imminent quarterly conference calls.

http://finance.yahoo.com/news/3-health-care-stocks-primed-150000250.html

#11494

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

Como nos tiene acostumbrada la muy jodida, bajará después de la publicación de resultadosl

#11495

Re: Threshold Pharmaceuticals, Inc (THLD): Opiniones

.... hubo alguna novedad o publicación ayer ??? .... no veo nada nuevo.

Brokers destacados